Last reviewed · How we verify
ABT-894
ABT-894 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1).
ABT-894 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1). Used for Relapsing multiple sclerosis, Primary progressive multiple sclerosis.
At a glance
| Generic name | ABT-894 |
|---|---|
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Drug class | S1P receptor modulator |
| Target | S1PR1 |
| Modality | Small molecule |
| Therapeutic area | Multiple Sclerosis, Autoimmune Diseases |
| Phase | Phase 2 |
Mechanism of action
By binding to S1PR1, ABT-894 modulates sphingosine-1-phosphate signaling, which plays a role in various cellular processes including inflammation and immune response. This mechanism is being explored for its potential therapeutic benefits in multiple sclerosis and other autoimmune diseases.
Approved indications
- Relapsing multiple sclerosis
- Primary progressive multiple sclerosis
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain (PHASE2)
- A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain (PHASE2)
- A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-894 CI brief — competitive landscape report
- ABT-894 updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI